TABLE 2.
Effects of early or delayed treatment with AMB-DOC or its derivates on survival of leukopenic micea and growth of C. albicans in the kidney
| Time of treatment | Drug usedb | Dose (mg of AMB/kg) | Log10 CFU/kidneyc at time of treatment | Day 7 after inoculation
|
||
|---|---|---|---|---|---|---|
| Survival rate (%) | Log10 CFU/kidneyc in surviving mice | No. of mice with sterile kidneys/no. of surviving mice | ||||
| 6 h | None (untreated) | 3.3 ± 0.2 | ||||
| Placebo (5-DW) | 0 | |||||
| AMB-DOC | 0.8 | 100 | 5.1 ± 0.6 | 0/10 | ||
| hAMB-DOC | 0.8 | 100 | 5.0 ± 0.6 | 0/10 | ||
| hAMB-DOC | 3 | 100 | 1.0 ± 0.8d | 3/10 | ||
| hcAMB-DOC | 0.8 | 100 | 5.2 ± 0.6 | 0/10 | ||
| hcAMB-DOC | 3 | 100 | 1.3 ± 0.5d | 0/10 | ||
| 16 h | None (untreated) | 4.2 ± 0.1 | ||||
| Placebo (5-DW) | 0 | |||||
| AMB-DOC | 0.1 | 0 | ||||
| hAMB-DOC | 0.6 | 100 | 5.1 ± 0.7 | 0/10 | ||
| hcAMB-DOC | 0.6 | 60 | 5.8 ± 0.8 | 0/6 | ||
a
Leukopenic mice were inoculated i.v. at time zero with 3 × 104 CFU of C. albicans; untreated mice died within 3 days after C. albicans inoculation.
b
AMB-DOC, its derivates, and placebo were administered i.v.
c
Each value is the geometric mean ± SD.
d
Significant decrease (P ≤ 0.001) from number of CFU at the time of treatment.